Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
37.96 ^USD	-3.09%		-3.01%	-17.42%

05-14	Transcript : Rhythm Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
05-08	BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49	MT

Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 07, 2024 at 07:10 am

Rhythm Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 25.97 million compared to USD 11.47 million a year ago. Net loss was USD 141.37 million compared to USD 52.18 million a year ago.

Basic loss per share from continuing operations was USD 2.35 compared to USD 0.92 a year ago.

Latest news about Rhythm Pharmaceuticals, Inc.

Transcript : Rhythm Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM	05-14
BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49	05-08	MT
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell	05-07	MT
Transcript : Rhythm Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (RYTM) RHYTHM PHARMACEUTICALS Reports Q1 Revenue $26M, vs. Street Est of $26.9M	05-07	MT
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting	05-06	CI
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	04-29	CI
Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	04-18	MT
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	04-01	MT
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, C2 Life Sciences, Llc, Perceptive Discovery ID LP	03-31	CI
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy	03-25	MT
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	03-25	CI
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	03-22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	03-22	MT
Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals	03-20	CI
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $627,520, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Transcript : Rhythm Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 07:30 AM	03-14
Rhythm Pharmaceuticals Says Planning to Add More Japanese Patients to Phase 3 Hypothalamic Obesity Trial	02-22	MT
Rhythm Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises; Shares Down Pre-Bell	02-22	MT
Transcript : Rhythm Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22

Chart Rhythm Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Sector

Biotechnology & Medical Research

Calendar

2024-06-18 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Rhythm Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.96 USD

Average target price

57.22 USD

Spread / Average Target

+50.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RHYTHM PHARMACEUTICALS, INC.	-17.42%	2.31B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs